Consequently, nonsynonymous mutation burden strongly induces reactivity of T‐cell and results in tumor regression in the context of anti‐PD‐1 therapy (Le et al., 2017; Riaz et al., 2017; Rizvi et al., 2015). Here, PDCD1 is linked to neoplasm.